Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00032162

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors

Sponsor: AGO Study Group

Conditions Cervical Cancer Endometrial Cancer Fallopian Tube Cancer Ovarian Cancer Sarcoma

Interventions carboplatin pegylated liposomal doxorubicin hydrochloride

Updated 6 times since 2017 Last updated: May 29, 2012 Started: Aug 31, 2001 Primary completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00032162, this PHASE1/PHASE2 trial focuses on Cervical Cancer and Endometrial Cancer and remains completed. Sponsored by AGO Study Group, it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AGO Study Group

Data source: AGO Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bremen, Germany , Dresden, Germany , Düsseldorf, Germany , Frankfurt, Germany , Frankfurt am Main, Germany , Greifswald, Germany , Göttingen, Germany , Hanover, Germany , Karlsruhe, Germany and 7 more locations